The Epidemiology Research Core (ERC) supports population-based research by providing access to metropolitan Detroit cancer cases and the cancer registry data for research. The Core also provides epidemiology consulting and collaborates with KCI members conducting investigations in cancer prevention, etiology, treatment and outcomes. This mission is achieved through services including rapid case ascertainment (RCA) for population-based case enrollment;collection of medical records and biospecimens for population-based cases;abstracting medical records for study-specific information for population-based cases;linkage of datasets to patient data for diagnostic, treatment, and outcomes data;identifying population-based control groups;oversight and support of population-based study participant recruitment and interviewing;and epidemiologic expertise and collaboration for the conduct of population-based investigations of cancer. These objectives are achievable because WSU and KCI house the Metropolitan Detroit Cancer Surveillance System (MDCSS), an NCI-funded population-based Surveillance Epidemiology and End Results (SEER) registry covering the metropolitan Detroit population of four million residents. This population represents a large number of minorities, with -25% of the 25,000 annual cancer diagnoses in the SEER catchment area being African American, making the population ideal for the study of health disparities. The ERC benefits KCI by centralizing access to SEER data and standardizing patient, physician and hospital interactions for research relying on identification of and access to study participants for population-based research.
The ERC provides the necessary support to KCI members and other investigators for access to and utilization of cancer registry data and patients for entry into population-based investigations of cancer prevention, etiology, treatment and outcomes. This type of population-based cancer research is made possible by providing investigator access to the MDCSS and national SEER population data through the ERC.
|Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12|
|Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5|
|Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7|
|Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6|
|Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018|
|Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202|
|Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54|
|Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867|
|Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84|
|Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830|
Showing the most recent 10 out of 321 publications